

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
Email ID: complianceofficer@concordbiotech.com

June 24, 2025

To The Manager, Listing Department National Stock Exchange of India Ltd. Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department BSE Limited Phiroze Jeejabhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960
---	---

Subject: Concord Biotech limited receives Establishment Inspection Report (EIR) for it's API facility at Dholka

Ref: Our Earlier intimation dated May 02,2025 regarding Intimation for completion of inspection by United States Food and Drug Administration

We are pleased to inform the exchanges that the company has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at our API facility at Dholka **from 28th April 2025 till 2nd May 2025.**

We would further like to inform that the USFDA has officially concluded its inspection, which is now closed under 21 CFR 20.64(d)(3). This closure indicates that no regulatory action is required, and the facility is permitted to continue its operations without any restrictions.

Thanking You,

For Concord Biotech Limited

Hina Patel
Company Secretary and Compliance Officer
(ACS:56541)